Molecular Partners is a biotech company listed on the SIX Stock Exchange in Zurich, Switzerland under the symbol MOLN. The company is pioneering the development of a novel class of targeted protein therapeutics termed DARPin® proteins in oncology and ophthalmology.
Cooperation possibilities
Molecular Partners has entered several agreements with pharma and biotech companies such as Allergan and Amgen. The company is actively seeking further partnerships for the co-development of innovative therapeutic products based on its innovative DARPin® platform.
- http://www.molecularpartners.com
- +41 44 755 77 00
- info@molecularpartners.com
- Patrick Amstutz, CEO